Companion Animal Vaccine Market, By Product Type (Live Attenuated Vaccine, Conjugated Vaccine, Inactivated Vaccine, Subunit Vaccine, Toxoid Vaccine, DNA Vaccine, and Recombinant Vaccine), By Animal Type (Canine, Feline, Equine, and Others), By Distributio

Companion Animal Vaccine Market, By Product Type (Live Attenuated Vaccine, Conjugated Vaccine, Inactivated Vaccine, Subunit Vaccine, Toxoid Vaccine, DNA Vaccine, and Recombinant Vaccine), By Animal Type (Canine, Feline, Equine, and Others), By Distribution Channel (Veterinary Clinics, Veterinary Hospitals, Veterinary Research Institutes, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Companion animal vaccines play an important role in improving the health of companion animals in a cost effective manner. These vaccines are also important for reducing viral diseases transmitted from animals to animals or animals to humans. The U.S. FDA Center for Veterinary Medicine (CVM) approves drugs for companion (pet) animals such as dogs, cats, and horses and for food-producing animals such as cattle, pigs, and chickens. Moreover, increasing initiatives from regulatory authorities for prevention of diseases such as viral diseases in companion animals are expected to boost the global companion animal market growth over the forecast period. For instance, in 2016, The American Animal Hospital Association (AAHA) has commissioned a task force of veterinary oncology experts to develop a set of guidelines that will help veterinary teams work with pet owners for tailored treatment plans that will improve the quality of life of pets with cancer.
Market Dynamics
The increasing approval and launch of novel companion vaccines, adoption of inorganic growth strategies such as acquisitions and collaborations by key players operating in the market, and rising research and development of novel vaccines are expected to drive the growth of global companion animal vaccine market over the forecast period. For instance, in March 2021, Virbac, a French animal care company, launched a vaccine called CANILEISH to prevent canine leishmaniosis, due to the increasing prevalence of canine leishmaniosis in several regions across the globe, especially in Southern Europe and South America.
Moreover, in June 2018, Zoetis received approval from the U.S. Department of Agriculture for marketing its first monovalent vaccine Fostera Gold PCV, used in the pork industry for swine that includes two genotypes of porcine circovirus type 2 (PCV2).
Key features of the study:
This report provides in-depth analysis of the global companion animal vaccine market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022 - 2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global companion animal vaccine market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Elanco Animal Health Incorporated, Boehringer Ingelheim GmbH, Ceva, Merck & Co., Inc., Virbac, Zoetis Inc, HIPRA, Biogénesis Bagó, and Ourofino Animal Health.
Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future market expansions and marketing tactics
The global companion animal vaccine market report caters to various stakeholders in this industry, including investors, product developers and manufacturers, distributors, healthcare organizations, research institutes, new entrants, and financial analysts
Stakeholders would greatly benefit in decision making through various strategy matrices used in analyzing the global companion animal vaccine market.
Detailed Segmentation:
Global Companion Animal Vaccine Market, By Product Type:
Attenuated Live Vaccine
Conjugate Vaccine
Inactivated Vaccine
Subunit Vaccine
Toxoid Vaccine
DNA Vaccine
Recombinant Vaccine
Global Companion Animal Vaccine Market, By Animal Type:
Canine
Feline
Equine
Others
Global Companion Animal Vaccine Market, By Distribution Channel:
Veterinary Clinics
Veterinary Hospitals
Veterinary Research Institute
Others
Global Companion Animal Vaccine Market, By Region:
North America
By Product Type
Attenuated Live Vaccine
Conjugate Vaccine
Inactivated Vaccine
Subunit Vaccine
Toxoid Vaccine
DNA Vaccine
Recombinant Vaccine
By Animal Type
Canine
Feline
Equine
Others
By Distribution Channel
Veterinary Clinics
Veterinary Hospitals
Veterinary Research Institute
Others
By Country
U.S.
Canada
Latin America
By Product Type
Attenuated Live Vaccine
Conjugate Vaccine
Inactivated Vaccine
Subunit Vaccine
Toxoid Vaccine
DNA Vaccine
Recombinant Vaccine
By Animal Type
Canine
Feline
Equine
Others
By Distribution Channel
Veterinary Clinics
Veterinary Hospitals
Veterinary Research Institute
Others
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Product Type
Attenuated Live Vaccine
Conjugate Vaccine
Inactivated Vaccine
Subunit Vaccine
Toxoid Vaccine
DNA Vaccine
Recombinant Vaccine
By Animal Type
Canine
Feline
Equine
Others
By Distribution Channel
Veterinary Clinics
Veterinary Hospitals
Veterinary Research Institute
Others
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Product Type
Attenuated Live Vaccine
Conjugate Vaccine
Inactivated Vaccine
Subunit Vaccine
Toxoid Vaccine
DNA Vaccine
Recombinant Vaccine
By Animal Type
Canine
Feline
Equine
Others
By Distribution Channel
Veterinary Clinics
Veterinary Hospitals
Veterinary Research Institute
Others
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Product Type
Attenuated Live Vaccine
Conjugate Vaccine
Inactivated Vaccine
Subunit Vaccine
Toxoid Vaccine
DNA Vaccine
Recombinant Vaccine
By Animal Type
Canine
Feline
Equine
Others
By Distribution Channel
Veterinary Clinics
Veterinary Hospitals
Veterinary Research Institute
Others
By Country
GCC
Israel
Rest of Middle East
Africa
By Product Type
Attenuated Live Vaccine
Conjugate Vaccine
Inactivated Vaccine
Subunit Vaccine
Toxoid Vaccine
DNA Vaccine
Recombinant Vaccine
By Animal Type
Canine
Feline
Equine
Others
By Distribution Channel
Veterinary Clinics
Veterinary Hospitals
Veterinary Research Institute
Others
By Country/Region
South Africa
Central Africa
North Africa
Company Profiles
Elanco Animal Health Incorporated *
Company Overview
Material Portfolio
Financial Performance
Key Highlights
Market Strategies
Boehringer Ingelheim GmbH
Ceva
Merck & Co., Inc.
Virbac
Zoetis Inc.
HIPRA
Biogénesis Bagó,
Ourofino Animal Health
“*” marked represents similar segmentation in other categories in the respective section.